The addition of pembrolizumab to neoadjuvant chemoradiotherapy did not increase the risk of developing postoperative anastomotic leakage for ESCC: an analysis from a prospective cohort-Reference-Cited by-同舟云学术

The addition of pembrolizumab to neoadjuvant chemoradiotherapy did not increase the risk of developing postoperative anastomotic leakage for ESCC: an analysis from a prospective cohort

Published:2024-08-20 Issue:1 Volume:24 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Qi Wei-Xiang,Li Shuyan,Li Huan,Chen Jiayi,Zhao Shengguang

Funder

Clinical Research Special Project of Shanghai Municipal Health Commission Health Industry

Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Project

National Natural Science Foundation of China

Shanghai Sailing Program

Beijing Science and Technology Innovation Medical Development Foundation

Shanghai Key Laboratory of Proton-therapy

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12885-024-12774-w.pdf

Reference32 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.

2. Zheng RSZS, Zeng HM, Wang SM, Sun KX, Chen R, Li L, Wei WQ, He J. Cancer incidence and mortality in China, 2016. JNCC 2022, 2(1):1–9.

3. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg. 2001;72(1):306–13.

4. Eyck BM, van Lanschot JJB, Hulshof M, van der Wilk BJ, Shapiro J, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, et al. Ten-year outcome of Neoadjuvant Chemoradiotherapy Plus surgery for esophageal Cancer: the Randomized Controlled CROSS Trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2021;39(18):1995–2004.

5. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z et al. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial. JAMA surgery 2021.